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Abstract
Background
Whether being metabolically healthy obese (MHO)—defined by the presence of obesity in
the absence of metabolic syndrome—is associated with subsequent cardiovascular dis-
ease (CVD) remains unclear and may depend on the participants’ age. We examined the
association of being MHO with CVD risk in the elderly.
Methods and Findings
This study included 5,314 individuals (mean age 68 years) from the prospective population-
based Rotterdam Study. We categorized our population in groups according to body mass
index (BMI) and presence and absence of metabolic syndrome, and estimated the hazard
ratio (HR) and 95% confidence interval (95%CI) for every group by using Cox proportional
hazard models. Among 1048 (19.7%) obese individuals we identified 260 (24.8%) MHO
subjects. Over 14 years of follow-up there were 861 incident CVD cases. In the multivariable
adjusted analysis, we did not observe an increased CVD risk in MHO individuals (HR 1.07,
95%CI 0.75–1.53), compared to normal weight individuals without metabolic syndrome.
CVD risk was increased by the presence of metabolic syndrome in normal weight (HR 1.35,
95%CI 1.02–1.80), overweight (HR 1.32, 95%CI 1.09–1.60) and obese (HR 1.33, 95%CI
1.07–1.66) individuals, compared to those with normal weight without metabolic syndrome.
In a mediation analysis, 71.3% of the association between BMI and CVD was explained by
the presence of metabolic syndrome.
Conclusions
In our elderly population, we found that the presence of obesity without metabolic syndrome
did not confer a higher CVD risk. However, metabolic syndrome was strongly associated
with CVD risk, and was associated with an increased risk in all BMI categories. Therefore,
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Introduction
Although obesity in young individuals is an established risk factor for cardiovascular disease
(CVD), the effect of obesity in the elderly seems to dilute with advancing age, rising towards
controversial discussions [1, 2]. The discrepancy between the findings at younger versus older
ages suggests that additional factors may alter the effect of obesity on risk of CVD. It is well
known that the presence of metabolic syndrome (a cluster of cardiovascular risk factors includ-
ing hypertension, dyslipidemia, hyperglycemia and abdominal obesity) differs among individu-
als with similar body mass index (BMI), which indicates that the risk of CVD within specific
categories of BMI could be heterogeneous [3, 4]. In this context, recent interest has focused on
a subgroup of obese individuals, termed the metabolically healthy obese (MHO), who despite
their increased BMI (BMI30kg/m2) seem to have an adequate metabolic profile and do not
have metabolic syndrome[3, 5].
The effect of being MHO on health outcomes remains controversial. While some studies
have reported no increased risk of CVD among MHO individuals [4, 5–7], several other studies
have shown an increased risk of CVD in this group [8–11]. For example, a 17 year follow-up
study of adults aged 39–63 years found an increased CVD risk for MHO individuals [8]. In
contrast, another study in women of 45 years and older, with 10 years follow-up, found no
increased CVD risk for obese individuals without metabolic syndrome [7]. It is important to
note that in these studies the mean age was below 65 years, indicating that information among
the elderly is scarce. In the elderly, the relation between body weight, body composition, and
health behaviors is different than in younger adults [12, 13]. Therefore, the impact of being
MHO could differ between younger, middle-aged and elderly adults.
In the current study, we aimed to study the role of being MHO in association with risk of
CVD in middle-aged and elderly individuals. We sought to examine the association of meta-
bolic syndrome with CVD among different BMI categories and to examine the contribution of
metabolic syndrome to the association between BMI and CVD.
Methods
Study design, setting, and population
This study was embedded within the Rotterdam Study (RS), a prospective population-based
cohort study among subjects aged 55 years or older in the municipality of Rotterdam, the Neth-
erlands [14]. The baseline examination of the initial cohort (RS-I) was completed between
1990 and 1993. In 2000–2001, the Rotterdam Study was extended (RS-II) with 3,011 partici-
pants who had become 55 years old or had moved into the study district. For the current
study, we used data from the participants attending the third examination of the original
cohort (RS-I visit 3, between 1997 and 1999; n = 4,797) and the participants attending the first
examination of the second cohort (RS-II visit 1, between 2000 and 2001; n = 3,011). We
excluded all participants with a history of CVD (coronary heart disease, cerebrovascular dis-
ease, or heart failure) at baseline (n = 1,505), those who did not visit the research center at base-
line for assessment of cardiovascular risk factors or BMI (n = 660), those who did not have
fasting plasma measurements (n = 289), and finally those who were underweight (BMI<18.5
kg/m2) at baseline (n = 40). This left a total of 5,314 individuals eligible for the present analyses.
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The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus MC
and by the Ministry of Health, Welfare and Sport of the Netherlands, implementing the “Wet
Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study)”. All participants
provided written informed consent to participate in the study and to obtain information from
their treating physicians. Detailed information on the design of the Rotterdam Study can be
found elsewhere [14].
Assessment of anthropometric, lifestyle exposures, and laboratory
measurements
Height and weight were measured with the participants standing without shoes and heavy
outer garments. BMI was calculated as weight divided by height squared (kg/m2). Waist cir-
cumference was measured at the level midway between the lower rib margin and the iliac crest
with participants in standing position without heavy outer garments and with emptied pockets,
breathing out gently. Information on education ( high school,< high school), smoking status
(current or former/never), alcohol use (drinking alcohol or not), and physical activity[15] were
obtained through interview. Blood pressure was measured in seated position and averaged
across two measures. Fasting triglycerides, total cholesterol and high-density lipoprotein
(HDL) cholesterol and glucose levels were measured using standard laboratory techniques [16,
17]. To assess kidney function we estimated the glomerular filtration rate (GFR), using the
Chronic Kidney Disease Epidemiology Collaboration CKD-EPI equation [18].
Metabolic syndrome and body mass index
Normal weight (18.5–25 kg/m2), overweight (25–29.9 kg/m2), and obese participants ( 30 kg/
m2) were categorized as either with or without metabolic syndrome based on the “Harmonized
metabolic syndrome definition” [19]. Participants were considered to have metabolic syn-
drome if they had 3 of the following five components: (1) waist circumference 102 cm in
men and 88 cm in women; (2) systolic blood pressure  130 mmHg and/or diastolic blood
pressure 85 mmHg or use of antihypertensive treatment; (3) fasting plasma triglycerides
150 mg/dL; (4) HDL cholesterol level< 40 mg/dL in men and< 50 mg/dL in women; (5) ele-
vated fasting glucose 100 mg/dL or treatment for diabetes mellitus. Consequently, this infor-
mation was used to create six phenotypes: normal weight, overweight and obese with or
without metabolic syndrome. MHO was defined as obesity without metabolic syndrome (i.e.
BMI 30kg/m2 and having 2 components of metabolic syndrome).
Definition of outcome
The main outcome measure under study was incident hard atherosclerotic CVD, composed of
fatal and non-fatal myocardial infarction, other coronary heart disease mortality, and fatal and
non-fatal stroke [20]. Definite and possible fatal coronary heart disease events are coded by
using the definitions applied within the Cardiovascular Health Study and Atherosclerosis Risk
in the Communities Study [21]. Stroke is defined as a syndrome of rapidly developing clinical
signs of focal (or global) disturbance of cerebral function, with symptoms lasting 24 hours or
longer or leading to death, with no apparent origin other than vascular [22]. Data on incident
CVD is collected using an automated follow-up system, through gathering information from
general practitioners in the study area and subsequent collection of information from letters of
medical specialists and discharge reports in case of hospitalization. A consensus panel, led by a
physician with expertise in field, adjudicated the diagnosis using standardized definitions. The
follow-up was complete until January 1, 2012.
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Statistical analysis
Baseline characteristics of the study population are presented as mean ± SD (or frequency
and percentage when appropriate) for the 6 phenotypes formed by the metabolic syndrome
across different BMI categories. In our main analysis, we used Cox proportional hazard
regression analysis to estimate the hazard ratio (HR) and 95% confidence interval (95%CI)
for the six phenotypes described above in association with CVD, using normal weight without
metabolic syndrome as the reference category. Additionally, we separately estimated the HR
and 95%CI for the associations of the BMI categories and metabolic syndrome with CVD.
Proportional hazards assumptions were confirmed in all Cox models, by visually comparing
the Kaplan-Meier curves of the different groups. The models were adjusted for age, gender,
smoking, cholesterol level, lipid-lowering medication use, GFR, alcohol use, education and
physical activity. We decided a priori not to adjust for systolic blood pressure, triglycerides,
HDL cholesterol, glucose, diabetes mellitus, and waist circumference, as they are all part of
the definition of metabolic syndrome [9]. Kaplan Meier analyses and log rank tests were used
to build plots for CVD incidence trends among the BMI categories, metabolic syndrome sta-
tus and the joint BMI and metabolic syndrome phenotypes. We did not observe a significant
association of gender with either BMI, metabolic syndrome or the joint BMI and metabolic
syndrome phenotypes. Moreover, we did not find an interaction between BMI and metabolic
syndrome.
In a mediation analysis, we examined whether metabolic syndrome could be considered a
mediator in the association between BMI and CVD risk. The percentage of excess risk medi-
ated was calculated as [(HRcon adj −HRcon + med adj)/(HRcon adj − 1)] × 100%, where HRcon adj is
the confounder-adjusted HR for CVD and HRcon + med adj is the confounder and mediator—
adjusted HR [23].
Sensitivity analyses. Due to the high competing risk of non-CVD death among the
elderly, we performed a competing risk analysis using the method proposed by Fine and Gray
[24]. Additionally, we repeated the main analysis in participants older than 65, to specifically
examine the associations in the elderly. Although there was no interaction between BMI or
metabolic syndrome with gender, we repeated our main analysis in men and women, because
of gender-differences in body fat distribution. Moreover, to show the independence of meta-
bolic syndrome over BMI, we adjusted for BMI (continuously and categorical) in the associa-
tion of metabolic status with CVD. Finally, to investigate the dose-response relation between
metabolic syndrome and CVD, we evaluated the risk of CVD according to the presence of one,
two, three, four, or five components of the metabolic syndrome.
Co-variables were missing in less than 5% of the participants, with the exception of treat-
ment for hypertension, which had 7.7% missing. We used the single imputation by the Expec-
tation Maximization method in SPSS. The analyses were performed using IBM SPSS Statistics
for Windows (IBM SPSS Statistics for Windows, Armonk, NY: IBM Corp) and R version 3.1.3
(R Foundation for Statistical Computing, Vienna, Austria).
Results
Characteristics of the study participants, stratified by BMI and metabolic syndrome, are shown
in Table 1. Among all participants, 57.2% (n = 3,038) were without metabolic syndrome and
19.7% (n = 1,048) were obese. The MHO phenotype represented 4.9% (n = 260) of the total
study population and 24.8% of the obese population. MHO subjects were more often women
and reported more physical activity compared to obese individuals with metabolic syndrome.
During a median follow-up of 10.3 years (interquartile range: 8.1–11.7 years), there were 861
(16.2%) incident CVD events.
Metabolically Healthy Obesity and CVD Risk
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In the association between BMI categories and CVD, we found that being overweight (HR
1.12, 95%CI: 0.96–1.30) or obese (HR 1.18, 95% CI: 0.97–1.44) was not significantly associated
with risk of CVD, compared to being normal weight. In contrast, individuals with metabolic
syndrome had an increased risk of CVD (HR: 1.27, 95% CI: 1.11–1.46), compared to individu-
als without metabolic syndrome.
In Table 2, we present the HRs (95% CIs) for the association between the joint BMI and
metabolic syndrome phenotypes with incident CVD. Compared to normal weight subjects
without metabolic syndrome, the HRs (95%CIs) were 1.08 (0.89–1.32) in overweight and 1.07
(0.75–1.53) in obese subjects without metabolic syndrome and 1.35 (95%CI, 1.02–1.80) in nor-
mal weight, 1.32 (1.09–1.60) in overweight and 1.33 (1.07–1.66) in obese subjects with meta-
bolic syndrome. Fig 1 presents the Kaplan-Meier survival curves of the cumulative incidence of
CVD by categories of BMI (Fig 1A), by presence of metabolic syndrome (Fig 1B) and as a func-
tion of the joint BMI and metabolic status phenotypes (Fig 1C). The cumulative incidences of
CVD were not different among categories of BMI (log-rank trend P = 0.395). However, the
cumulative incidence was higher in individuals with metabolic syndrome compared to those
without (log-rank trend P<0.001). As expected, the cumulative incidence of CVD was higher
in normal weight, overweight and obese individuals with metabolic syndrome, than in individ-
uals without metabolic syndrome (log-rank trend P< 0.001). In the mediation analysis
(Table 3), the percentage of excess risk mediated by metabolic syndrome in the association
between BMI (as a continuous variable) and CVD was 71.3%; that is, 71.3% of the association
between BMI and CVD could be explained by metabolic syndrome. By categorizing BMI, this
proportion increased up to 73.1%.
Table 1. Baseline characteristics of study population across the categories of metabolic health status and bodymass index.
No metabolic syndrome (n = 3038) Metabolic syndrome (n = 2276)
Normal weight Overweight Obese Normal weight Overweight Obese
n, % 1444 (47.5) 1334 (43.9) 260 (8.6) 306 (13.4) 1182 (51.9) 788 (34.7)
Women, % 859 (59.5) 686 (51.4) 203 (78.1) 197 (64.4) 689 (58.3) 568 (72.1)
Age, years 68.2 ± 8.0 68.1 ± 8.0 68.3 ± 8.1 70.1 ± 8.5 68.8 ± 8.1 68.1 ± 7.9
High education, % 520 (36.1) 552 (41.3) 132 (50.7) 124 (40.5) 498 (42.1) 381 (48.3)
Current smokers, % 346 (24.0) 226 (16.9) 40 (15.4) 92 (30.1) 254 (21.5) 117 (14.8)
Alcohol use, % 868 (60.1) 721 (54.0) 177 (68.1) 194 (63.4) 690 (58.4) 554 (70.3)
Physical activity, METHour/week 86.6 ± 42.9 87.1 ± 45.5 85.3 ± 44.1 81.7 ± 43.4 82.0 ± 40.7 80.4 ± 44.0
Estimated glomerular filtration rate, GFR 77.2 ± 13.6 76.3 ± 13.5 76.4 ± 15.7 73.1 ± 15.4 74.1 ± 14.7 75.4 ± 15.2
Waist circumference, cm 83.2 ± 8.3 92.1 ± 8.0 100.3 ± 9.4 89.1 ± 8.2 97.3 ± 7.5 107 ± 10.0
BMI, kg/m2 23.0 ± 1.5 26.9 ± 1.3 32.3 ± 2.3 23.6 ± 1.2 27.6 ± 1.4 33.4 ± 3.1
Triglycerides, mg/dl 103.1 ± 39.2 109.1 ± 42.3 107.6 ± 30.7 181.1 ± 79.3 173.2 ± 77.0 172.4 ± 86.2
Fasting glucose, mg/dl 97.5 ± 14.7 100.0 ± 16.7 98.6 ± 15.1 115.8 ± 34.5 114.5 ± 28.6 120.3 ± 33.5
HDL cholesterol, mg/dl 61.2 ± 14.7 57.5 ± 13.4 59.7 ± 13.8 46.1 ± 15.1 46.7 ± 12.1 48.2 ± 14.0
Systolic blood pressure, mmHg 137.1 ± 21.3 139.9 ± 20.6 140.3 ± 23.1 150 ± 19.7 149.4 ± 19.8 149.4 ±18.8
Diastolic blood pressure, mmHg 74.2 ± 10.7 76.4 ± 10.6 77.2 ± 10.5 77.1 ± 10.5 79.2 ± 10.9 79.9 ± 10.9
Treatment for hypertension, n (%) 154 (10.7) 231 (17.3) 73 (28.1) 64 (20.9) 376 (31.8) 325 (41.2)
Total cholesterol, mg/dl 224.4 ± 36.0 227.4 ± 36.4 228.3 ± 35.9 232.8 ± 39.2 229.7 ± 37.8 226.6 ± 37.0
Treatment for hyperlipidemia, n (%) 82 (5.7) 93 (7.0) 16 (6.2) 50 (16.3) 158 (13.4) 111 (14.1)
n, number; MET, metabolic equivalent of task; BMI, body mass index; HDL, high-density lipoprotein.
Values are means ± standard deviation or numbers (percentages).
doi:10.1371/journal.pone.0154273.t001
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Sensitivity analyses
S1 Table shows that the HRs (95%CIs) from the competing risk approach were not substan-
tially different from our original analysis. Additionally, when we repeated the main analysis in
adults 65 and older, or in men and women separately, we found similar results (S2 and S3
Tables). Moreover, the association of metabolic status with CVD did not largely change after
we further adjusted for BMI (S4 Table). The new HR (95%CI) of the presence of metabolic syn-
drome was 1.25 (1.08–1.46), when we adjusted for BMI continuously. Finally, when we exam-
ined the dose-response relation between metabolic syndrome components and CVD, we
observed that the risk of CVD increased stepwise according to the presence of one, two, three,
four, or five components of metabolic syndrome (S5 Table).
Table 2. Association of the joint bodymass index andmetabolic syndrome phenotypes with cardio-
vascular disease.
N Events HR (95%CI)
No metabolic syndrome
normal weight 1444 203 1 (Reference)
overweight 1334 205 1.08 (0.89–1.32)
obese 260 36 1.07 (0.75–1.53)
Metabolic syndrome
normal weight 306 63 1.35 (1.02–1.80)
overweight 1182 219 1.32 (1.09–1.60)
obese 788 135 1.33 (1.07–1.66)
N, number; HR, hazard ratio; CI, confidence interval.
Hazard ratios and 95%CI are for the multivariable model adjusted for age, gender, smoking, total
cholesterol, treatment for hyperlipidemia, estimated glomerular filtration rate (GFR), alcohol, physical
activity and education.
doi:10.1371/journal.pone.0154273.t002
Fig 1. Cumulative incidence of cardiovascular disease as a function of follow-up time according to bodymass index categories (A), metabolic
syndrome (B) and the joint bodymass index andmetabolic syndrome phenotypes (C). (A) Red: “normal weight” (1,750 individuals), dark blue:
“overweight” (2,516 individuals), light blue: “obese” (1,048 individuals).These incident curves do not differ significantly from each other over the follow-up
(log-rank test, P = 0.395). (B) Red: “without metabolic syndrome” (3,038 individuals), dark blue: “with metabolic syndrome” (2276 individuals).These incident
curves differ significantly from each other over the follow-up (log-rank test, P = 0.001). (C) Solid lines indicate individuals without metabolic syndrome and
dotted lines individuals with metabolic syndrome. Red: “normal weight” (including 1444 without metabolic syndrome and 306 with metabolic syndrome); dark
blue: “overweight” (including 1334 without metabolic syndrome and 1182 with metabolic syndrome); light blue: “obese” (including 260 without metabolic
syndrome and 788 with metabolic syndrome). These incident curves differ significantly from each other over the follow-up (log-rank test, P = 0.001).
doi:10.1371/journal.pone.0154273.g001
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Discussion
In this population-based study of 5,314 middle-aged and elderly individuals, 19.7% of the pop-
ulation was obese, of which 24.8% were without metabolic syndrome (i.e. MHO). Our study
yields three key findings. First, compared to normal weight individuals without metabolic syn-
drome, MHO subjects were not at significant increased risk of CVD. Second, regardless of
being normal weight, overweight or obese, the presence of metabolic syndrome consistently
increased CVD risk. Third, 71.3% of the association between BMI and CVD was explained by
metabolic syndrome. These findings highlight the importance of assessing CVD risk irrespec-
tive of BMI in an older population, and stress the importance of metabolic syndrome in the
elderly.
Previous studies evaluating the association between metabolically healthy obesity and CVD
risk have shown inconsistent results [4, 5–11]. While some studies reported no increased risk
of CVD among MHO individuals [4, 5–7], several other studies have shown an increased CVD
risk in this group [8–11]. In agreement with our study, Meigs et al., in an 11-year follow-up
study of 2,902 men and women (mean age of 53 years), reported that MHO individuals do not
have an increased risk of CVD in the Framingham Offspring Study [5]. Similarly, a report
from the Women’s Ischemia Syndrome Evaluation (WISE) study showed that the presence of
metabolic syndrome, but not BMI, predicted 3-year risk of cardiovascular death, in 21 to
86-year-old women referred for angiography [4]. Moreover, a large prospective study of 25,626
women aged 45 years and older, followed up to 10 years, found that MHO individuals were not
at increased risk of CVD [7]. Additionally, this study showed that the presence of metabolic
syndrome conferred a higher risk of developing CVD than BMI [7]. In contrast with these
studies, Hinnouho et al., in a 17 year follow-up study, including men and women aged 35–55
years, found that MHO individuals were at increased risk of incident CVD, compared with
normal weight individuals without metabolic syndrome [8]. Moreover, in contrast to our find-
ings, these authors revealed a gradual increased CVD risk for overweight and obese individuals,
compared to normal weight persons, both in individuals with and without metabolic syn-
drome. Similarly to Hinnouho et al, Thomsen et al reported that MHO individuals are at
higher risk of developing myocardial infarction and ischemic heart disease [9]. Additionally,
this short follow-up (median 3.6 years) study of 71,527 men and women aged 20–100 years
showed that both in individuals with and without metabolic syndrome, there were increasing
cumulative incidences of myocardial infarction and ischemic heart disease going from normal
weight through overweight to obesity. Furthermore, in their study, metabolic syndrome
explained only 12% of the risk attributed to BMI in the association with myocardial infarction
and ischemic heart disease, whereas in our study metabolic syndrome explained 71.3% of the
risk attributed to BMI in association with CVD.
Table 3. Percentage of excess risk mediated by metabolic syndrome in association between bodymass index and cardiovascular disease.
Exposure Mediator HR confounder adjusted HR confounder and mediator adjusted PERM, %
BMI (continuously) Metabolic syndrome 1.0174 1.0053 71.3
BMI (categorically) Metabolic syndrome 1.0901 1.0242 73.1
HR, hazard ratio; PERM, percentage of excess risk mediated; BMI, body mass index
Percentage of excess risk mediated (PERM) was calucalted as ((HRconfounder adjusted−HRconfounder+mediator adjusted)/(HRconfounder adjusted -1))*100%. Hazard
ratios are for the multivariable model adjusted for age, gender, smoking, cholesterol, treatment for hyperlipidemia, estimated glomerular filtration rate
(GFR), alcohol, physical activity and education. Body mass index was categorized as normal weight (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2), and
obese (30kg/m2).
doi:10.1371/journal.pone.0154273.t003
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The different findings regarding the association between metabolically healthy obesity and
CVD risk in the studies mentioned above could reflect differences in the age range of the par-
ticipants included in the different studies. To explain the importance of age in the association
between BMI, metabolic syndrome and CVD, two possibilities could be considered. First, stud-
ies have shown that the magnitude of the relation between BMI and CVD risk weakens with
age [25–27]. Indeed, in our study there was no evidence for a dose-response increase in CVD
risk within BMI categories in individuals with or without metabolic syndrome, whereas other
studies conducted in younger populations showed a progressive increase in CVD risk, going
from normal weight through overweight to obesity [8, 9]. Although body weight and BMI may
remain relatively unchanged with advancing age, there is a change in body composition, fol-
lowed by visceral fat increases and muscle mass decreases [28]. Hereby, elderly individuals can
be considered overweight by body fat standards, without having a BMI above 25. Conse-
quently, BMI becomes a less accurate reflection of fat mass [29] and BMI alone may therefore
not be a precise predictor of cardiovascular risk in elderly. On the other hand, metabolic syn-
drome is an established predictor of future CVD, and as we also showed in our study, the
increased risk of CVD starts with the presence of just one component of the metabolic syn-
drome. Moreover, the prevalence of metabolic syndrome increases in older individuals [30]
and was 42.8% in our population. Consequently, the metabolic syndrome becomes a more rele-
vant condition in the elderly. Taken together, these findings stress the importance of metabolic
syndrome over BMI in the development of future CVD among older adults, compared to
young adults.
The mechanisms underlying the healthy metabolic profile of metabolically healthy obesity
are still unclear. It has been suggested that the location, metabolic activity and histological
characteristics of adipose tissue may determine metabolic health among obese individuals,
whereas the amount of adipose tissue is less crucial [31]. In addition, the amount of years that
an individual has been obese might play a role [32]. Moreover, studies have shown that MHO
individuals have lower levels of C-reactive protein [33] and higher levels of insulin sensitivity,
compared to obese individuals with metabolic syndrome [34]. Additionally, there is some evi-
dence that obese individuals with metabolic syndrome are less fit than MHO individuals [35].
In our study, MHO participants had higher levels of physical activity than their obese counter-
parts with metabolic syndrome, which supports this last statement. However, a previous study
has proposed that MHO is not a permanent state of the healthy metabolic profile, but rather a
transient phase, moving toward glucose-metabolic abnormalities [8]. Therefore, it might be
wise to re-evaluate the metabolic status of MHO individuals on a regular basis.
In our study, the presence of metabolic syndrome in normal weight individuals conferred a
higher risk of CVD compared to obese individuals without metabolic syndrome, when we com-
pared both groups to normal weight individuals without metabolic syndrome. Moreover, nor-
mal weight individuals with metabolic syndrome had a higher cumulative incidence of CVD
than obese individuals with metabolic syndrome. Our study showed that the presence of meta-
bolic syndrome in normal weight individuals was accompanied by a higher smoking prevalence
and lower levels of physical activity, compared to obese individuals without metabolic syn-
drome. This finding is in accordance with a previous study [3], that showed that MHO individ-
uals were more often nonsmokers and met the current physical activity guidelines more
frequently than normal weight individuals with metabolic syndrome. Our observation that the
cumulative incidence of CVD was higher in normal weight subjects with metabolic syndrome,
compared to their obese counterparts, could be explained by the fact that normal weight indi-
viduals with metabolic syndrome were older and more often smokers than obese individuals
with metabolic syndrome. Moreover, we found that normal weight individuals with metabolic
syndrome had a lower proportion of treatment for hypertension at the baseline compared to
Metabolically Healthy Obesity and CVD Risk
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obese individuals with metabolic syndrome. Remarkably, the baseline systolic blood pressure
in both groups was similar. This may suggest that the obese individuals are more likely to be
screened for CVD and subsequently receive medication.
Strengths of the current study include the prospective study design, large sample size, long
follow-up, high follow-up rate, reliable assessment of CVD events and detailed assessment of
lifestyle factors, components of the metabolic syndrome and cardiovascular risk factors. How-
ever, several limitations should be considered. First, our conclusions are drawn from the base-
line measurements. In our analyses, we were not able to account for changes in BMI and
metabolic factors during follow-up. Therefore, a degree of misclassification, due to changes in
these risk factors over time might have occurred. Second, our study population included only
Caucasian men and women above 55 years. Therefore, results from the present study cannot
be generalized to other age-groups or ethnics groups.
To conclude, in our population-based study of middle-aged and elderly adults, MHO indi-
viduals were not at increased risk of CVD. However, the presence of the metabolic syndrome
was associated with future cardiovascular risk similarly in normal weight, overweight and
obese individuals Additionally, we showed that the association between BMI and CVD was
largely (73.1%) explained by the presence of metabolic syndrome. Although it remains prudent
to recommend weight loss in overweight and obese individuals and the benefits that these
interventions can achieve expand beyond cardiovascular events, our results suggest that pre-
ventive interventions targeting cardiometabolic risk factors in older individuals should be con-
sidered regardless of weight status.
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